Multivariable analysis for RI
| Risk factor . | Group . | N . | D . | HR (95% CI) . | P . |
|---|---|---|---|---|---|
| Pretreatment × IPSS-R score change | |||||
| Chemotherapy | Same | 116 | 31 | ||
| Improving | 307 | 94 | 0.66 (0.43-1.01) | .05 | |
| Progressive | 90 | 24 | 1.16 (0.67-1.99) | .6 | |
| HMAs | Same | 86 | 25 | ||
| Improving | 168 | 65 | 1.17 (0.73-1.86) | .5 | |
| Progressive | 59 | 19 | 1.90 (1.03-3.47) | .04 | |
| Other | Same | 42 | 11 | ||
| Improving | 95 | 33 | 1.00 (0.50-2.00) | >.99 | |
| Progressive | 53 | 19 | 2.33 (1.09-4.98) | .03 | |
| Untreated | Same | 165 | 20 | ||
| Improving | 67 | 6 | 0.58 (0.23- 1.45) | .2 | |
| Progressive | 179 | 32 | 1.75 (0.99- 3.07) | .05 | |
| Adjustment factors | |||||
| IPSS-R score at diagnosis | Very low | 78 | 14 | ||
| Low | 309 | 56 | 1.06 (0.59-1.92) | .8 | |
| Intermediate | 453 | 105 | 1.62 (0.90-2.93) | .11 | |
| High | 373 | 108 | 2.46 (1.34-4.54) | .004 | |
| Very high | 214 | 96 | 4.51 (2.39-8.51) | <.001 | |
| Interval from diagnosis to HCT | 1427 | 379 | 1.02 (0.96-1.08) | .5 | |
| Age at HCT (dec) | 1427 | 379 | 0.97 (0.87-1.08) | .5 | |
| Conditioning | Standard | 482 | 113 | ||
| Reduced | 945 | 266 | 1.36 (1.07-1.74) | .01 | |
| Donor | Related | 515 | 151 | ||
| Unrelated | 912 | 228 | 0.84 (0.69-1.04) | .11 |
| Risk factor . | Group . | N . | D . | HR (95% CI) . | P . |
|---|---|---|---|---|---|
| Pretreatment × IPSS-R score change | |||||
| Chemotherapy | Same | 116 | 31 | ||
| Improving | 307 | 94 | 0.66 (0.43-1.01) | .05 | |
| Progressive | 90 | 24 | 1.16 (0.67-1.99) | .6 | |
| HMAs | Same | 86 | 25 | ||
| Improving | 168 | 65 | 1.17 (0.73-1.86) | .5 | |
| Progressive | 59 | 19 | 1.90 (1.03-3.47) | .04 | |
| Other | Same | 42 | 11 | ||
| Improving | 95 | 33 | 1.00 (0.50-2.00) | >.99 | |
| Progressive | 53 | 19 | 2.33 (1.09-4.98) | .03 | |
| Untreated | Same | 165 | 20 | ||
| Improving | 67 | 6 | 0.58 (0.23- 1.45) | .2 | |
| Progressive | 179 | 32 | 1.75 (0.99- 3.07) | .05 | |
| Adjustment factors | |||||
| IPSS-R score at diagnosis | Very low | 78 | 14 | ||
| Low | 309 | 56 | 1.06 (0.59-1.92) | .8 | |
| Intermediate | 453 | 105 | 1.62 (0.90-2.93) | .11 | |
| High | 373 | 108 | 2.46 (1.34-4.54) | .004 | |
| Very high | 214 | 96 | 4.51 (2.39-8.51) | <.001 | |
| Interval from diagnosis to HCT | 1427 | 379 | 1.02 (0.96-1.08) | .5 | |
| Age at HCT (dec) | 1427 | 379 | 0.97 (0.87-1.08) | .5 | |
| Conditioning | Standard | 482 | 113 | ||
| Reduced | 945 | 266 | 1.36 (1.07-1.74) | .01 | |
| Donor | Related | 515 | 151 | ||
| Unrelated | 912 | 228 | 0.84 (0.69-1.04) | .11 |
Multivariable Cox cause-specific hazards models for relapse incidence, with interactions between pretreatment and change in IPSS-R score. The total number of patients in each group and the number of events are reported in the N and D columns, respectively. The interval from diagnosis to HCT is in years, and age at HCT is in decades. Effect estimates are given with 95% CIs. Corresponding P values are calculated using the Wald test. All interaction effects between pretreatment and IPSS-R score change include both corresponding main effects.
dec, decades.